Blueprint Medicines Corporation Stock News

Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.

Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2021 Results - Earnings Call Transcript

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to ($1.86), which were in line

CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 202

HOUSTON and CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strateg

CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.

CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera

This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

CAMBRIDGE, Mass., June 16, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) f

CAMBRIDGE, Mass., June 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on June 1, 2021, the Compensation Committee of Blueprint Medicines' Board

CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.

CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the presentation of updated Phase 1/2 ARROW trial data demonstrating durable clinical bene

CAMBRIDGE, Mass., May 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter, MBA, Ph.D.

CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of